XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended March 31,
Dollars in millions20232022
Net product sales$11,048 $11,308 
Alliance revenues144 188 
Other revenues145 152 
Total Revenues$11,337 $11,648 
Revenue Recognition Gross-To-Net Adjustments
The following table summarizes GTN adjustments:
Three Months Ended March 31,
Dollars in millions20232022
Gross product sales$17,288 $16,650 
GTN adjustments (a)
Charge-backs and cash discounts(2,091)(1,763)
Medicaid and Medicare rebates(2,482)(2,084)
Other rebates, returns, discounts and adjustments(1,667)(1,495)
Total GTN adjustments(6,240)(5,342)
Net product sales$11,048 $11,308 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $87 million and $74 million for the three months ended March 31, 2023, and 2022, respectively.
Revenue from External Customers by Products and Services
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended March 31,
Dollars in millions20232022
In-Line Products
Eliquis$3,423 $3,211 
Opdivo2,202 1,923 
Pomalyst/Imnovid832 826 
Orencia764 792 
Sprycel429 483 
Yervoy508 515 
Mature and other products467 537 
Total In-Line Products 8,625 8,287 
New Product Portfolio
Reblozyl206 156 
Abecma147 67 
Opdualag117 6 
Zeposia78 36 
Breyanzi71 44 
Onureg34 23 
Inrebic25 18 
Camzyos29 — 
Sotyktu16 — 
Total New Product Portfolio723 350 
Total In-Line Products and New Product Portfolio9,348 8,637 
Recent LOE Products(a)
Revlimid1,750 2,797 
Abraxane239 214 
Total Recent LOE Products1,989 3,011 
Total revenues$11,337 $11,648 
United States$8,033 $7,694 
International3,149 3,727 
Other(b)
155 227 
Total revenues$11,337 $11,648 
(a)    Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.
(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.